Schizochytrium sp. seed powder

About

What it is and where it shows up.

Schizochytrium sp. seed powder is a dried, microencapsulated or spray-dried powder form of DHA-rich oil extracted from the marine single-cell microalga Schizochytrium sp., used as a source of the omega-3 long-chain polyunsaturated fatty acid docosahexaenoic acid (DHA) in foods, infant formula, and dietary supplements. It is produced via fermentation of the microalga under controlled conditions, followed by oil extraction and conversion to a powder form using food-grade excipients.

Safety summary

The regulatory and scientific consensus.

Multiple regulatory bodies including the US FDA and EFSA have concluded there are no safety concerns for the general adult population at typical intake levels, with no adverse effects reported in animal or human studies up to 1.5 g DHA/person/day. The ingredient has achieved GRAS status in the US across multiple notifications and Novel Food authorisation in the EU. High-dose DHA supplementation (>3 g/day combined DHA+EPA) from food supplements is not recommended for pregnant or lactating women without medical supervision due to limited specific data in those populations.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
EFSA (European Food Safety Authority) (European Union)	Approved	Authorised as a Novel Food under Regulation (EU) 2015/2283 and predecessor Regulation (EC) No 258/97 since Commission Decision 2003/427/EC. Use in food supplements up to 3 g/day combined DHA+EPA for the general adult population is considered safe. DHA addition to infant formula is mandatory at 20–50 mg/100 kcal per Regulation (EU) 2016/127. Schizochytrium limacinum holds Qualified Presumption of Safety (QPS) status 'for production purposes only'.source
Food Standards Agency (FSA) / Food Standards Scotland (FSS) (United Kingdom)	Approved	Original UK safety assessment in 2012 concluded the novel food was safe under intended conditions of use; authorisations incorporated into the UK assimilated Novel Food Regulation 2017/2470 post-Brexit. Ongoing FSA/FSS assessment (RP2180) confirmed proposed specification changes are safe and not nutritionally disadvantageous.source
FDA (Food and Drug Administration) (United States)	Approved	Multiple GRAS notices accepted (GRN 137, 553, 677, 732, 844, 913, 1008, 1128). DHA-rich oil powder from Schizochytrium sp. is GRAS at use levels up to 125% of those specified in 21 CFR 184.1472(a)(3) for menhaden oil; intended as sole DHA source not to exceed 1.5 g DHA/person/day.source

Who should approach with care

Whose guidance would steer them away.

Pregnancy — EFSA concluded that food supplement use providing more than 3 g/day combined DHA+EPA is not recommended for pregnant women without medical guidance, as specific safety data in this population at higher doses is limited.

Lactation — EFSA's 2014 NDA Panel opinion explicitly excluded pregnant and lactating women from the general population finding of safety at up to 3 g/day DHA+EPA in food supplements, recommending medical consultation.

Infants — While DHA from Schizochytrium sp. is approved and even mandated in infant formula at 20–50 mg/100 kcal, supplemental doses beyond formula use levels in infants should only be used under medical supervision.

Heart Disease — High-dose omega-3 supplementation (>3 g/day) may have anticoagulant/antiplatelet effects; individuals on anticoagulant therapy or with cardiovascular conditions should consult a physician before using high-dose DHA powder products.

Research citations

The sources behind this verdict.

1other. Safety Assessment on the Change of Specification of the Novel Food Schizochytrium sp. Oil Rich in DHA and EPA (RP2180), 2026. science.food.gov.uk
2EFSA. Safety of Schizochytrium sp. oil as a novel food pursuant to Regulation (EU) 2015/2283, 2020. efsa.europa.eu
3PubMed. Safety of Schizochytrium sp. oil as a novel food pursuant to Regulation (EU) 2015/2283 (PMC full text), 2020. pmc.ncbi.nlm.nih.gov
4FDA. GRAS Notice 844: Algal oil (55% docosahexaenoic acid) from Schizochytrium sp. strain FCC-3204, 2019. fda.gov
5FDA. GRAS Notice 732: Docosahexaenoic acid oil produced in Schizochytrium sp., 2018. fda.gov

Independently researched5 citations